![]() |
|
|
Vol. 26, Issue 7, 681-688, July 1998
-Methylbenzyl)-1-Aminobenzotriazole
Department of Pharmacology and Toxicology, University of Western
Ontario
N-Aralkylated derivatives of 1-aminobenzotriazole are
well-established, mechanism-based inhibitors of cytochrome P450 (CYP or
P450). In this study, the kinetics of inactivation of CYP2B-dependent 7-pentoxyresorufin O-depentylation (PROD) and
CYP1A-dependent 7-ethoxyresorufin O-deethylation (EROD)
activities by enantiomers of
N-(
-methylbenzyl)-1-aminobenzotriazole (
MB) were
compared. The racemic mixture (±)-
MB, as well as the enantiomers
(
)-
MB and (+)-
MB, produced a time-, concentration-, and
NADPH-dependent loss of PROD and EROD activity in hepatic microsomes
from phenobarbital-treated guinea pigs. The rates of PROD inactivation
by (
)-
MB were significantly faster than for (+)-
MB. Consistent
with this, the derived maximal kinact was
also significantly greater for (
)-
MB than for (+)-
MB (0.49 vs. 0.35 min
1). In contrast, the
concentrations required for the half-maximal rate of inactivation
(Ki) were equivalent for (
)-
MB and
(+)-
MB, whereas the degree of competitive inhibition of PROD
activity was greater for (+)-
MB. No significant differences were
found among (
)-
MB, (+)-
MB, and (±)-
MB with respect to
mechanism-based inactivation (kinact = 0.18, 0.16, and 0.17 min
1, respectively) or
competitive inhibition of EROD activity. No differences were found for
the maximal extent of PROD or EROD inhibition or the loss of spectral
P450 after an extended 30-min incubation with the inhibitors. We
conclude that mechanism-based inactivation of guinea pig CYP2B, but not
CYP1A, isozymes by
MB occurs in a stereoselective manner, most
likely as a result of a difference in the balance between metabolic
activation and deactivation for the
MB enantiomers.
This article has been cited by other articles:
![]() |
P. Lu, S. B. Singh, B. A. Carr, Y. Fang, C. D. Xiang, T. H. Rushmore, A. D. Rodrigues, and M. Shou Selective Inhibition of Dog Hepatic CYP2B11 and CYP3A12 J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 518 - 528. [Abstract] [Full Text] [PDF] |
||||